Padeliporfin assigned FDA Orphan Drug Designation for upper tract urothelial cancer
The FDA has granted approval for the Phase 3 clinical trial of Padeliporfin ImPACT in patients with low-grade upper tract urothelial cancer (UTUC), and Fast Track designation for the treatment of adult patients with low-grade and unifocal high-grade UTUC.
Source:
Biospace Inc.